HomeCompareSYNH vs ARCC

SYNH vs ARCC: Dividend Comparison 2026

SYNH yields 4.65% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SYNH wins by $2.6K in total portfolio value· pulled ahead in Year 4
10 years
SYNH
SYNH
● Live price
4.65%
Share price
$42.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.1K
Annual income
$626.90
Full SYNH calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — SYNH vs ARCC

📍 SYNH pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYNHARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYNH + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYNH pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYNH
Annual income on $10K today (after 15% tax)
$395.53/yr
After 10yr DRIP, annual income (after tax)
$532.87/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, SYNH beats the other by $531.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYNH + ARCC for your $10,000?

SYNH: 50%ARCC: 50%
100% ARCC50/50100% SYNH
Portfolio after 10yr
$25.8K
Annual income
$314.03/yr
Blended yield
1.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

SYNH
Analyst Ratings
12
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$72.00
+67.5% upside vs current
Range: $25.00 — $105.00
Altman Z
1.4
Piotroski
7/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYNH buys
0
ARCC buys
0
No recent congressional trades found for SYNH or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYNHARCC
Forward yield4.65%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$27.1K$24.5K
Annual income after 10y$626.90$1.16
Total dividends collected$5.5K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$72.00$21.88

Year-by-year: SYNH vs ARCC ($10,000, DRIP)

YearSYNH PortfolioSYNH Income/yrARCC PortfolioARCC Income/yrGap
1$11,165$465.33$11,381$541.15$216.00ARCC
2$12,432$485.57$12,621$284.08$189.00ARCC
3$13,808$505.31$13,827$145.31$19.00ARCC
4← crossover$15,299$524.50$15,062$73.43+$237.00SYNH
5$16,913$543.12$16,364$36.89+$549.00SYNH
6$18,658$561.14$17,757$18.49+$901.00SYNH
7$20,543$578.54$19,258$9.25+$1.3KSYNH
8$22,576$595.30$20,880$4.63+$1.7KSYNH
9$24,768$611.43$22,636$2.32+$2.1KSYNH
10$27,129$626.90$24,539$1.16+$2.6KSYNH

SYNH vs ARCC: Complete Analysis 2026

SYNHStock

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.

Full SYNH Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this SYNH vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYNH vs SCHDSYNH vs JEPISYNH vs OSYNH vs KOSYNH vs MAINSYNH vs HTGCSYNH vs GBDCSYNH vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.